GHK-Cu Peptide Shows Promise Against Silicosis by Reducing Lung Damage

Silicosis is a severe and progressive chronic lung disease, the most common type of pneumoconiosis, primarily affecting workers with long-term exposure to crystalline silica (CS). This condition leads to debilitating lung inflammation and fibrosis, for which there is currently no specific medication. This study aimed to investigate the therapeutic potential of GHK-Cu, a naturally occurring tripeptide known for its antioxidant effects, in treating silicosis and elucidate its underlying molecular mechanisms.

The study found that GHK-Cu treatment significantly attenuated both lung inflammation and fibrosis in the experimental silicosis mouse model. Importantly, GHK-Cu achieved these therapeutic benefits without causing significant systemic toxicity. The researchers identified that GHK-Cu can bind to peroxiredoxin 6 (PRDX6), suggesting a direct molecular interaction. This binding and the subsequent therapeutic effects were partly related to GHK-Cu's ability to inhibit the crystalline silica (CS)-induced oxidative stress specifically within alveolar macrophages. This reduction in oxidative stress is a crucial mechanism. The most important finding is that GHK-Cu acts as a potential drug by attenuating alveolar macrophage oxidative stress, which in turn significantly reduces the progression of pulmonary inflammation and fibrosis.